Potential Dangers From Zinc (and Copper) Supplementation: Implications for Alzheimer Disease and AMD

A closer look at the data.

By Jerry Rapp, PhD, and Jerome Sherman, OD

Alzheimer disease (AD) is an age-related neurodegenerative disease characterized biochemically by an abnormal buildup of amyloid β (Aβ) protein.1

BACKGROUND ON AD

The divalent cations zinc (Zn++) and copper (Cu++) have both been associated with the development of AD. Brain homeostasis of Zn and Cu is severely disrupted in AD,2 An alteration in brain Zn homeostasis, resulting in either above or below normal levels, has been implicated in the pathogenesis of senile dementia characteristic of AD. Excess Zn and Cu at high concentrations seems to promote the neurotoxic effects of Aβ.3,4 High levels of Zn may generate brain neurotoxicity and neurodegeneration by interfering with the normal functioning of ligand-gated ion channels.5 Excess Cu contributes to the toxic effects of Zn relating to the aggregation of Aβ and formation of the amyloid plaques prevalent in AD.6-8

AD AND AMD

There are similarities between the operative pathological mechanisms in AD and several types of retinal degenerative disease, including age-related macular degeneration (AMD).9 It has even been suggested that retinal changes in AMD may function as a biological marker for AD diagnosis and progression.9 In addition, there are data supporting an association between AMD and cognitive impairment.10

AREDS

Prior to the AREDS (Age-Related Eye Diseases Study) investigations, the effects of Zn supplementation on the development and progression of AMD were inconclusive, with some studies showing at least some beneficial effects,11,12 while other studies showed no association.13-16

The original AREDS investigation (AREDS Report No. 8)17 demonstrated that high levels of Zn supplementation (80 mg per day—as much as 10 times the recommended dietary allowance, plus 2 mg of Cu) together with high levels of vitamins C, E, and beta-carotene, reduced the risk of progression to advanced AMD by 25% and the risk of moderate vision loss by 19%. The AREDS2 trial lowered the daily dose of Zn for one subgroup of subjects to 25 mg per day. There was no statistically significant effect on progression to advanced AMD between the higher dose Zn used in the original AREDS formulation compared to the lower dose Zn used in AREDS2.18 Yet, the National Eye Institute continues to recommend the high (80 mg) daily dose of Zn.

GENETIC FACTORS

There are currently a total of 19 genomic loci that have been identified as being potential risk factors in t he development of AMD.19 The first and probably most important of these in terms of risk was identified by four independent investigations in 2005 and involves a single nucleotide polymorphism in complement factor H (CFH).20-23 CFH is a negative modulator of the alternate complement pathway. This discovery linked the pathogenesis of AMD to the complement cascade and its concomitant inflammation.

A more recent article (2008) demonstrated that high levels of Zn (and copper) cause CFH to aggregate, thereby inhibiting its ability to downregulate the complement cascade.24 This finding has, in turn, led to a new hypothesis concerning the effect of Zn on AMD—that it has opposing roles; specifically that Zn may be protective at later stages of disease, whereas it may trigger development of AMD in the disease’s early stages.25 So, a combination of the previously mentioned single nucleotide polymorphism in CFH and the presence of high levels of Zn may inactivate a key component of the alternate complement pathway to such an extent that the inflammatory process is not properly controlled, thereby significantly increasing the risk of developing AMD.

Another gene implicated in AMD is APOE,19 which codes for apolipoprotein E, a major component of a specific type of lipoprotein called very-low-density lipoproteins. Very-low-density lipoproteins remove excess cholesterol from the blood and carry it to the liver for processing.

Mutants of both CFH and APOE are also involved in the development of AD. The same CFH polymorphism, Y402H, that is a major risk factor for AMD is also associated with AD.26 In addition, both APOE and Zn are involved in Aβ aggregation and deposition.27

Add to all this the recent study28 which demonstrated that for AMD patients with one or two CFH risk alleles and no ARMS2 risk alleles, supplementation with Zn was associated with increased progression to advanced AMD.

CONCLUSION

With an elderly population of patients already at risk for both AD and AMD based solely on age, and with all the aforementioned overlap in biochemical mechanisms and genetic factors between the two conditions, is it scientifically reasonable and justifiable for the NEI to discourage genetic testing for AMD and to continue to recommend a daily supplement containing a high dose of Zn?

Jerry Rapp, PhD, is a professor, specializing in biochemistry, in the Department of Biological and Vision Sciences at SUNY College of Optometry, New York, New York. He acknowledged no relevant financial interest. Dr. Rapp may be reached at (212) 938-5786; j.rapp@sunyopt.edu.

Jerome Sherman, OD, is a Distinguished Teaching Professor in the Department of Clinical Education at the State University of New York College of Optometry and he is also in private practice at the Eye Institute and Laser Center, New York, New York. He acknowledged no relevant financial interest. Dr. Sherman may be reached at (212) 938-5862; j.sherman@sunyopt.edu.

  1. Yuan Y, Niu F, Lu Y, Lu N. Zinc and its effects on oxidative stress in Alzheimer’s disease. Neurol Sci. 2014; doi:10.1007/s10072-014-1668-x.
  2. Bush AI. The metal theory of Alzheimer’s disease. J Alzheimers Dis. 2013;33:S277-S281.
  3. Kawahara M, Mizuno D, Koyama H, et al. Disruption of zinc homeostasis and the pathogenesis of senile dementia. Metallomics. 2014;6:209-219.
  4. Faller P, Hureau C, Berthoumieu 0. Role of metal ions in the self-assembly of the Alzheimer’s amyloid l3 peptide. Inorg Chem. 2013;52:12193-12206.
  5. Morris DR, Levenson CW. Ion channels and zinc: Mechanisms of neurotoxicity and neurodegeneration. J Toxicol. 2012; doi:10.1155/2012/785647.
  6. Yao F, Zhang R, Tian H, Li X. Studies on the interactions of copper and zinc ions with beta-amyloid peptides by a surface plasmon resonance biosensor. Int J Mol Sci. 2012;13:11832-11843.
  7. Tougu V, Tiiman A, Palumaa P. Interactions of Zn(II) and Cu(II) ions with Alzheimer’s amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. Metallomics. 2011;3:250-261.
  8. Faller P. Copper and zinc binding to amyloid-beta: coordination, dynamics, aggregation, reactivity and metal-ion transfer. Chembiochem. 2009;10:2837-2845.
  9. Sivak JM. The aging eye: Common degenerative mechanisms between the Alzheimer’s brain and retinal disease. Invest Ophthalmol Vis Sci. 2013;54:871-880.
  10. Rozzini L, Riva M, Ghilardi N, et al. Cognitive dysfunction and age-related macular degeneration. J Alzheimers Dis Other Demen. 2013. doi:10.1177/1533317513517032.
  11. Newsome DA, Swartz M, Leone NC, et al. Oral zinc in macular degeneration. Arch Ophthalmol. 1988;106:192-198.
  12. Mares-Perlman JA, Klein R, Klein BEK, et al. Association of zinc and antioxidant nutrients with agerelated maculopathy. Arch Ophthalmol. 1996;114:991-997.
  13. Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 1992;110:1701-1708.
  14. Stur M, Tittl M, Reitner A, Meisinger V. Oral zinc and the second eye in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1996;37:1225-1235.
  15. Smith W, Mitchell P, Webb K, Leeder SR. Dietary antioxidants and age-related maculopathy. The Blue Mountains eye study. Ophthalmology. 1999;106:761-767.
  16. VandenLangenberg GM, Mares-Perlman JA, Klein R, et al. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Study. Am J Epidemiol. 1998;148:204-214.
  17. Age-related eye disease study research group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-1436.
  18. Aronow NE, Chew EY. Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions. Curr Opin Ophthalmol. 2014. doi:10.1097/ICU.0000000000000046.
  19. The AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45:433-439e2.
  20. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
  21. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.
  22. Edwards AO, Ritter R III, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
  23. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-7232.
  24. Nan R, Jayesh G, Lengyel I, Perkins SJ. Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulatory factor H and its possible implications for function and disease. J Mol Biol. 2008;384:1341-1352.
  25. Lengyel I, Peto, T. Cure or cause: opposing roles for zinc in age-related macular degeneration. Expert Rev Ophthalmol. 2008;3:1-4.
  26. Zetterberg M, Landgren S, Andersson ME, et al. Association of complement factor H y402h gene polymorphism with Alzheimer’s disease.Am J Med Genet B Neuropsychiatr Genet. 2008;147B:720-726.
  27. Lee JY, Cho E, Kim TY, et al. Apolipoprotein e ablation decreases synaptic vesicular zinc in the brain. Biometals. 2010;23:1085-1095.
  28. Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology. 2013;120:2317- 2323.